Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • June 2023
  • Case
  • HBS Case Collection

Verve Therapeutics: Taking DNA Editing to Heart

By: Shikhar Ghosh and Shweta Bagai
  • Format:Print
  • | Language:English
  • | Pages:21
ShareBar

Abstract

Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing the risk of heart attacks. Built on decades of post-doctoral and lab research led by CEO Sekar (Sek) Kathiresan, a trained cardiologist and academic, Verve used gene editing – akin to a molecular surgical procedure—for a curative intent. Not only had the medicine reached human trials in record time, but Verve incorporated new innovations that could allow the technology to be used more widely. The company successfully built a solid syndicate of investors and raised a total of $860 million. Unlike other gene editing or gene therapy companies that focused on rare diseases affecting small populations, Verve’s approach was the first example of a gene editing treatment that could potentially benefit millions of people.
Verve’s lead investor was interested in creating Verve 2.0 and apply the company’s expertise to cure a range of rare metabolic diseases. Should Sek continue to build out the core product aimed at treating heart disease, or should he apply the technology to other adjacent diseases? Would this be a potential distraction from Verve’s core mission?

Keywords

AI; Genetic Engineering; Medicine; Health Care and Treatment; Genetics; Innovation Strategy; Business and Stakeholder Relations; Medical Specialties; Innovation and Invention; Entrepreneurship; Biotechnology Industry

Citation

Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
  • Educators
  • Purchase

About The Author

Shikhar Ghosh

Entrepreneurial Management
→More Publications

More from the Authors

    • March 2025
    • Faculty Research

    Helium Mobile

    By: Shikhar Ghosh, Jorge Tamayo and Mahesh Ramakrishnan
    • March 2025 (Revised May 2025)
    • Faculty Research

    NEAR Protocol: Self-Sovereignty in the Age of AI

    By: Shikhar Ghosh, Liang Wu and Mahesh Ramakrishnan
    • March 2025
    • Faculty Research

    Metaphysic AI: Rethinking the Value of Human Expertise

    By: Zoë B. Cullen, Shikhar Ghosh and Shweta Bagai
More from the Authors
  • Helium Mobile By: Shikhar Ghosh, Jorge Tamayo and Mahesh Ramakrishnan
  • NEAR Protocol: Self-Sovereignty in the Age of AI By: Shikhar Ghosh, Liang Wu and Mahesh Ramakrishnan
  • Metaphysic AI: Rethinking the Value of Human Expertise By: Zoë B. Cullen, Shikhar Ghosh and Shweta Bagai
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.